阿培利司治疗CLOVES综合征一例
CLOVES综合征是PIK3CA基因突变所致的罕见先天性过度生长疾病,属PROS谱系。本文报告一例CLOVES综合征患者,在淋巴管囊肿减容术和西罗莫司治疗后,接受低剂量阿培利司同情用药,淋巴管瘤体积显著缩小且臀部组织过度生长得到控制。
要点
- 低剂量阿培利司同情用药可缩小CLOVES综合征患者淋巴管瘤体积。
- 阿培利司可阻止CLOVES综合征患者臀部组织过度生长进展。
- 低剂量PI3K抑制可能带来超越PROS疾病特异性特征缓解的附加获益。
核心结论
- 低剂量阿培利司同情用药显著缩小CLOVES综合征患者淋巴管瘤体积并阻止臀部组织过度生长进展。
- 低剂量PI3K抑制可能提供超越PROS疾病特异性特征缓解的附加获益。
研究设计与样本
- 本文为单例CLOVES综合征患者的病例报告。
主要发现
- 患者在淋巴管囊肿减容术和西罗莫司治疗后开始低剂量阿培利司同情治疗。
- 阿培利司显著缩小淋巴管瘤体积并阻止臀部区域组织过度生长进展。
关键数值与推荐
- 阿培利司为选择性抑制剂,竞争性结合胞内PI3K/AKT信号通路中PIK3的p110a亚基。
- 一项19例PROS患者非对照病例系列中,低剂量阿培利司同情用药效果显著且不良反应少,未损害线性生长。
临床怎么用
- CLOVES综合征患者在手术减容和西罗莫司治疗后,可考虑低剂量阿培利司同情用药。
- 低剂量PI3K抑制可能为PROS患者提供超越疾病特异性特征缓解的附加获益。
局限性
- 本文为单例病例报告,无法确立因果关系或推广至所有CLOVES综合征患者。
- 阿培利司在该患者中的疗效和安全性需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CLOVES syndrome is a rare congenital overgrowth disorder caused by mutations in the phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) gene. It is part of the PIK3CA-related overgrowth syndrome (PROS) spectrum and its treatment is challenging. PROS malformations have traditionally been treated by surgery, but research into pharmacological treatments capable of blocking the PIK/AKT/mTOR pathway has increased over the past decade. The results have been promising and suggest that compassionate use of these treatments in patients with PROS disorders could have clinical benefits. Another promising drug is alpelisib (BYL719), which is a selective inhibitor that competitively binds to the p110a subunit of PIK3 in the intracellular PI3K/AKT signalling pathway. Compassionate use of low-dose alpelisib had striking effects in an uncontrolled case series of 19 PROS patients, several with life-threatening complications. Moreover, there were few adverse effects and the treatment did not impair linear growth, despite the young age of many of the patients. We present the case of a patient with CLOVES syndrome who was started on compassionate treatment with alpelisib after surgical debulking of a cystic lymphangioma and treatment with sirolimus. This promising drug significantly reduced the size of the lymphangioma and prevented progression of the tissue overgrowth in the gluteal region. This case suggests that low-dose PI3K inhibition may provide collateral benefits that extend beyond mitigation of disease-specific features of PROS.
引用
- Garreta Fontelles G, Pardo Pastor J, Grande Moreillo C, et al. Alpelisib to treat CLOVES syndrome, a member of the PIK3CA-related overgrowth syndrome spectrum. Br J Clin Pharmacol. 2022. PMID: 35146800. doi:10.1111/bcp.15270
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。